Triveni Bio Inc., a US-based biotech company developing a genetics-informed precision medicine approach to develop treatments for immunological and inflammatory (I&I) disorders, announced on Wednesday that Bhaskar Srivastava, M.D., Ph.D., has joined the company as chief medical officer (CMO).

Triveni says that Dr Srivastava will play a critical role as it advances its lead asset (TRIV-509) into the clinic in the first half of 2025 and brings second-generation combination approaches into the clinic in 2026.

The company claims that TRIV-509 - a half-life extended monoclonal antibody inhibitor of both kallikreins (KLK) 5 and 7 - has demonstrated superior efficacy relative to IL-4R inhibition in multiple atopic dermatitis animal models.

'We are thrilled to welcome Bhaskar to the team,' said Vishal Patel, Ph.D., Triveni Bio chief executive officer. 'He arrives at a key moment for the company, equipped with an impressive track record of leading dermatology strategy and clinical programs. Bhaskar's extensive training as a dermatologist and immunologist will further our goal of bringing innovation for I&I diseases.'

Prior to joining Triveni Bio, Dr Srivastava served as senior vice president, Clinical Development at Nimbus Therapeutics, where he advanced several novel clinical programs. Before Nimbus, he held senior clinical development roles at the Johnson & Johnson Innovative Medicine (formerly known as Janssen Pharmaceuticals), developing early-phase clinical programs in dermatology and rheumatology. A board-certified dermatologist, Dr Srivastava practiced medicine as an assistant professor of Dermatology at the Yale School of Medicine.